Who owns Praxis Precision Medicines, Inc. (PRAX)? Elite investor 13F holders
3 tracked elite investors reported holding Praxis Precision Medicines, Inc as of 2026-06-30, including Polen Capital Management, D.E. Shaw, Tudor Investment. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Polen Capital Management | PRAXIS PRECISION MEDICINES I | SHARE | 2026-06-30 | 2026-08-04 00:00:00 | 2427897.00 USD | 7252.000000 | Shares | reduce | Original filing |
| D.E. Shaw | PRAXIS PRECISION MEDICINES I | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 1720820.00 USD | 5140.000000 | Shares | buy | Original filing |
| Tudor Investment | PRAXIS PRECISION MEDICINES I | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 730847.00 USD | 2183.000000 | Shares | buy | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.